Back to the Top
Dear All
Is there any published report indicating that controlled/slow release
of a
drug that undergoes significant first pass effect in liver as well as is
labile to presystemic metabolism in GIT (by esterases, microflora as
well
as epithelial metabolism) will actually decrease the bioavailability
of the
drug.
Pls provide the reference and if possible, a copy of the article.
Regards
Rajesh
Want to post a follow-up message on this topic?
If this link does not work with your browser send a follow-up message to PharmPK@boomer.org with "Bioavailability with high first pass effect from sustained release formulation" as the subject | Support PharmPK by using the |
Copyright 1995-2011 David W. A. Bourne (david@boomer.org)